The No. 1 medical platform in women’s healthcare
First written in FY2020. 2 of 5 entries say "Restated". Latest entry: 2026-03-24.
No other company in this theme has enough history to compare yet.
- 2026-03-24AdvancedOther Disclosures
「This initiative will further deepen our expertise in women’s healthcare and significantly strengthen our ability to execute our strategy of continuing to create new value in women’s healthcare.」
The company’s previous policy of expanding its contribution to women’s healthcare has taken concrete form through an initiative involving joint development with external companies, the acquisition of manufacturing and commercialization rights, and the assumption of research and development costs. - FY2025-H1ReframedAnnual report
「Over the next 5 years, the company is pursuing four growth strategies: "expanding contributions to women's healthcare," "expanding contributions through the biosimilars business," "contributing earnings through the global CMO business," and "laying the groundwork for and identifying the next growth drivers."」
The previous goal of becoming the "No. 1 healthcare platform" in women's healthcare has been reframed under the Long-Term Vision 2035 as the growth strategy of "expanding contributions to women's healthcare." - FY2022RestatedAnnual report
「The company aims to become the No. 1 healthcare platform in women's healthcare by developing new drugs centered on hormone preparations, pursuing initiatives in peripheral areas beyond pharmaceuticals, and delivering value efficiently and effectively through digitalization.」
It continues to pursue the goal of becoming the No. 1 healthcare platform in women's healthcare through new drugs, peripheral areas and digitalization. - FY2021RestatedAnnual report
「The company aims to become the No. 1 healthcare platform in women's healthcare by developing new drugs centered on hormone preparations, pursuing initiatives in peripheral areas beyond pharmaceuticals, and delivering value efficiently and effectively through digitalization.」
It continues to pursue the policy of becoming the No. 1 healthcare platform in women's healthcare through new drugs, peripheral areas and digitalization. - FY2020First statedAnnual report
「The company aims to become the No. 1 healthcare platform in women's healthcare by developing new drugs centered on hormone preparations, pursuing initiatives in peripheral areas beyond pharmaceuticals, and delivering value efficiently and effectively through digitalization.」
It sets out a new goal of becoming the No. 1 healthcare platform in women's healthcare by combining new drugs, peripheral areas and digitalization.